Alnylam to Webcast Presentations at Upcoming March Investor Conferences

Rhea-AI Summary

Alnylam Pharmaceuticals (Nasdaq: ALNY) will present at three upcoming virtual conferences. The events are the Cowen 41st Annual Healthcare Conference on March 1 at 2:40 pm ET, the H.C. Wainwright Global Life Sciences Conference on March 9 at 7:00 am ET, and the Barclays Global Healthcare Conference on March 10 at 1:15 pm ET. Each presentation will have a live audio webcast available on the Company’s website, with replays accessible within 48 hours.

Alnylam specializes in RNA interference therapeutics aimed at treating various severe diseases.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences which are being held virtually:

• Cowen 41^st Annual Healthcare Conference on Monday, March 1, 2021 at 2:40 pm ET
• H.C. Wainwright Global Life Sciences Conference on Tuesday, March 9, 2021 at 7:00 am ET
• Barclays Global Healthcare Conference on Wednesday, March 10, 2021 at 1:15 pm ET

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after each event.

About Alnylam

Alnylam (Nasdaq: ALNY) is leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare genetic, cardio-metabolic, hepatic infectious, and central nervous system (CNS)/ocular diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach for the treatment of a wide range of severe and debilitating diseases. Founded in 2002, Alnylam is delivering on a bold vision to turn scientific possibility into reality, with a robust RNAi therapeutics platform. Alnylam’s commercial RNAi therapeutic products are ONPATTRO^® (patisiran), GIVLAARI^® (givosiran), and OXLUMO™ (lumasiran), as well as Leqvio^® (inclisiran), which is being developed and commercialized by Alnylam’s partner Novartis. Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development. Alnylam is executing on its “Alnylam P⁵x25” strategy to deliver transformative medicines in both rare and common diseases benefiting patients around the world through sustainable innovation and exceptional financial performance, resulting in a leading biotech profile. Alnylam is headquartered in Cambridge, MA. For more information about our people, science and pipeline, please visit www.alnylam.com and engage with us on Twitter at @Alnylam or on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005748/en/

FAQ

What is Alnylam Pharmaceuticals presenting at the Cowen 41st Annual Healthcare Conference?

Alnylam Pharmaceuticals will provide an overview presentation on March 1, 2021, at 2:40 pm ET.

When is Alnylam's presentation at the H.C. Wainwright Global Life Sciences Conference?

Alnylam's presentation is scheduled for March 9, 2021, at 7:00 am ET.

What time will Alnylam present at the Barclays Global Healthcare Conference?

Alnylam's presentation at the Barclays Global Healthcare Conference is on March 10, 2021, at 1:15 pm ET.

Where can I listen to Alnylam's conference presentations?

Live audio webcasts of Alnylam's presentations will be available on their website.

How soon will replays of Alnylam's conference presentations be available?

Replays of Alnylam's presentations will be available within 48 hours after each event.